NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine the safety and efficacy of the bortezomib, lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma. We are looking for the highest dose of the combination that can be given safely and see how well it works as a combination in newly diagnosed patients.

Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Brigham and Women's Hospital

Beth Israel Deaconess Medical Center

Massachusetts General Hospital

Celgene Corporation

Millennium Pharmaceuticals, Inc.

---

ClinicalTrials.gov Identifier: NCT00378105

Official Title: An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

First Posted : September 19, 2006

https://clinicaltrials.gov/ct2/show/NCT00378105

---

Drug: Bortezomib

Drug: Lenalidomide

Drug: dexamethasone

---

Locations

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

---

Blood; 2010

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

https://pubmed.ncbi.nlm.nih.gov/20385792/